TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Benefit of Preoperative Supplemental Vitamin D in Patients Undergoing Brain Tumor Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent of patient or legal representative~* 25(OH)D level below 20ng/dL~Exclusion Criteria:~* Other trial participation, including previous participation in the pilot trial~* Pregnant or lactating women~* Hypercalcemia~* Hyperphosphatemia~* Tuberculosis~* Sarcoidosis~* History of nephrolithiasis~* History of hyperparathyroidis~* Medications that interfere with vitamin D metabolism~* Renal Insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vitamin D (Type: EXPERIMENTAL): Intervention patients will be received a single dose of 300000 IU vitamin D via intramuscular injection
- control (Type: OTHER): Control patients will not be received any intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Long Term Inhalation of Hypertonic Saline in Subjects With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of CF (sweat tests/genotype)~* The subject, or their legal guardian for children under 18 years old, must provide written informed consent.~* The subject must be in stable clinical condition at the time of and for a period of 14 days prior to their recruitment into the study.~* Age \> 6 years old~* FEV1 \> 40% predicted for height, age and gender~* Proven or anticipated compliance with therapy or study protocol~* Regular attendee at a Cystic Fibrosis Clinic (\> 2 visits per year)~* Able to reproducibly perform lung function tests (spirometry)~* Relatively stable nutritional status (\< 2 kg weight loss in last 6 months and \< 5 kg weight loss in last year)~* Known to have normal (for CF subject) laboratory tests - haematology, biochemistry, immunology, coagulation, etc.~Exclusion Criteria:~* Requiring home oxygen (pO2 \<55mmHg or pCO2 \>50mmHg) or assisted ventilation.~* Considered terminally ill or listed for transplantation (either lung or liver). Subjects that are listed for transplant after being enrolled in the trial are eligible to continue in the trial.~* Subjects colonised with Burkholderia cepacia. However, if a subject becomes colonised with B. cepacia during the trial, they should continue in the trial. Subjects should be considered to be B. cepacia positive if they have had even a single lifetime isolate. In these subjects, spirometry should be measured on a dedicated spirometer.~* Cigarette smoker.~* Exposure to investigational drugs within the past 30 days.~* Major haemoptysis (\> 60 mL in a single episode) within the last twelve months.~* Concurrent illnesses eg. cor pulmonale, clinically significant liver disease (portal hypertension, varices).~* Known allergy to quinine sulphate, Glucose 6-phosphate dehydrogenase deficiency.~* Immune thrombocytopaenic purpura.~* Pregnant or lactating females.~* At risk females unwilling to use appropriate contraception to prevent pregnancy for the duration of their enrolment in the study.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CASA: Care and Support Access in HIV Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
PATIENTS -~Inclusion Criteria:~* HIV positive~* men who have sex with men attending one of 2 study site clinics~* 18-35 years~Exclusion Criteria:~* acute illness requiring medical attention~* cognitive impairment

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Patients at Intervention Site (Type: ACTIVE_COMPARATOR): Staff receives CASA Education
- Patients at CONTROL site (Type: NO_INTERVENTION): Staff does not receive CASA Education

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cigarette Pack Inserts for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18 or older~* Have smoked at least 100 cigarettes in their lifetime~* Smoked at least 10 cigarettes a day in the prior month.~Exclusion Criteria:~* Use of other nicotine products besides cigarettes in the prior month.~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Standard cigarette packs (control) (Type: NO_INTERVENTION): Participants will be provided with a 2 week supply of their preferred brand of cigarettes, with the only alteration being the small health warning message on the side of the pack, whose textual content will be the same as that used for the pictorial warning label conditions.
- Cigarette packs with inserts only (Type: EXPERIMENTAL): Participants will be provided with a 2 week supply of their preferred brand of cigarettes, with packs altered to include inserts with four different rotating messages to promote response efficacy beliefs (2 inserts on the benefits of cessation) or self-efficacy to quit (2 inserts with cessation tips).
- Cigarette packs with pictorial warnings only (Type: EXPERIMENTAL): Participants will be provided with a 2 week supply of their preferred brand of cigarettes, with packs altered to include four different rotating pictorial warnings showing the consequences of smoking and that cover 50% of the front and back of the pack.
- Cigarette packs with inserts and pictorial warnings (Type: EXPERIMENTAL): Participants will be provided with a 2 week supply of their preferred brand of cigarettes, with packs altered to include inserts with four rotating efficacy messages (see description above) and four rotating pictorial warnings (see above).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has T2DM~* Has HbA1c between 6.5% (48 mmol/mol) and 8.0% (64 mmol/mol) on stable dose(s) of antihyperglycemic agent(s), including insulin~* Has pre-existing cardiovascular disease~Exclusion Criteria:~* Has a history of type 1 diabetes mellitus or ketoacidosis.~* Is not able to take sitagliptin

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* HIV infected~* Viral load greater than 10,000 copies/ml within 30 days prior to study entry~* Weigh more than 5.5 lbs at the time of enrollment~* Agree to take 2 nucleoside reverse transcriptase inhibitors (NRTIs) in addition to LPV/RTV~* Have consent of parent or guardian willing to provide signed informed consent and to have the infant followed at a PACTG site~Exclusion Criteria~* Currently taking a nonnucleoside reverse transcriptase inhibitor or protease inhibitor (PI) while on study~* Previously used LPV/RTV. Patients who were treated previously with other PIs are not excluded. Prior or concurrent maternal treatment with LPV/RTV is not excluded.~* For patients less than 6 weeks old at time of enrollment, less than 34 weeks gestation at delivery OR for patients 6 or more weeks old at time of enrollment, less than 32 weeks gestation at delivery~* Any laboratory toxicity of Grade 3 or greater. Hyperlipasemia of Grade 2 or higher is also excluded.~* Newly diagnosed acute opportunistic or serious bacterial infection requiring therapy at the time of enrollment~* Chemotherapy for active cancer~* Certain medications~* Any other clinically significant conditions, other than HIV infection, that would interfere with the study

- Gender: ALL
- Minimum Age: 14 Days
- Maximum Age: 6 Months
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Two-Weekly Intravenous Mircera for the Treatment of Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* male or female patients, \>=18 years of age;~* chronic renal anemia (Hb concentration 8.0g/dL - 10.0g/dL);~* no prior erythropoietin stimulating agent (ESA) therapy.~Exclusion Criteria:~* blood transfusion within the previous 4 weeks;~* poorly controlled hypertension;~* significant acute or chronic bleeding;~* active malignant disease;~* congestive heart failure (NYHA Class IV).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mircera (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Escitalopram (Lexapro) for Depression MS or ALS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between 18 and 70 years of age with documented ALS or MS,~* DSM-IV episode of non-psychotic Major Depression,~* ≥14 score on the 17-item HAM-D,~* Ability to give informed consent.~Exclusion Criteria:~* History of psychotic disorders,~* Psychotic depression,~* Bipolar depression,~* Suicide risk,~* History of substance abuse in the previous 6 months,~* History of unstable medical disorders,~* Pregnancy or planning for pregnancy,~* Severity of ALS or MS that limits participating in the study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Escitalopram (Type: EXPERIMENTAL): All patients will receive escitalopram 20 mg daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~* Chronic hepatitis C viral infection~* Plasma HCV RNA level lower limit ≥ 10,000 IU/ml assessed by quantitative polymerase chain reaction (qPCR) or equivalent at screening (no upper limit)~* HCV genotype 2 or 3~* No previous treatment for hepatitis C infection~Exclusion criteria:~* Evidence of cirrhosis at the time of screening~* Evidence of hepatocellular carcinoma at the time of screening~* Any other cause of relevant liver disease other than HCV~* Alanine aminotransferase (ALT) ≥ 10 times upper limit of normal (ULN)~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ALV 1000 mg (Type: EXPERIMENTAL): Alisporivir (ALV) 600 mg twice daily (BID) for 1 week, followed by ALV 1000 mg once daily (QD) during Weeks 2 to 24.
- ALV 600 mg+RBV (Type: EXPERIMENTAL): Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with ribavirin (RBV) during Weeks 2 to 24.
- ALV 800 mg+RBV (Type: EXPERIMENTAL): Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
- ALV 600 mg+PEG (Type: EXPERIMENTAL): Alisporivir (ALV) 600 mg BID with Peginterferon alfa-2a (PEG) for 1 week, followed by ALV 600 mg QD with PEG once weekly during Weeks 2 to 24.
- PEG+RBV (Type: ACTIVE_COMPARATOR): Peginterferon alfa-2a (PEG) and RBV during Weeks 1 to 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be at least 18 years of age.~* Males and females with a documented diagnosis of UC at least 4 months prior to entry into the study.~* Subjects with moderately to severely active UC based on Mayo score criteria.~* Subjects must have failed or be intolerant of at least one of the following treatments for UC:~  * Corticosteroids (oral or intravenous).~ * Azathioprine or 6 mercaptopurine (6 MP).~ * Anti TNF-alpha therapy.~Exclusion Criteria:~* Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of Crohn's disease.~* Subjects with disease limited to distal 15 cm.~* Subjects without previous treatment for UC (ie, treatment naïve).~* Subjects displaying clinical signs of fulminant colitis or toxic megacolon.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tofacitinib 10 mg BID (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects chronically infected with HCV genotype 1 (Phase 2a and Phase 2b)~* Subjects chronically infected with HCV genotype 4 (Phase 2b only)~* HCV RNA viral load of ≥ 10\*5\* IU/mL at screening~* BMI of 18 - 35 kg/m² at screening~Exclusion Criteria:~* Cirrhosis (Phase 2a only)~* Decompensated cirrhosis (Phase 2b)~* Co-infection with HBV or HIV~* Hepatocellular carcinoma~* Prior treatment with anti-HCV drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Phase 2a: Arm 1 (Type: EXPERIMENTAL): None
- Phase 2a: Arm 2 (Type: PLACEBO_COMPARATOR): None
- Phase 2b: Arm 1 (Type: EXPERIMENTAL): None
- Phase 2b: Arm 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Adults must have a diagnosis of HS for at least 1 year prior to Baseline.~* HS lesions must be present in at least two distinct anatomical areas, one of which must be at least Hurley Stage II or Hurley Stage III.~* Subject must have stable HS for at least 60 days prior to Screening visit and at Baseline visit.~* Subject must have experienced an inadequate response to at least a 90-day treatment of oral antibiotics for treatment of HS.~* Subject must have a total AN count of greater than or equal to 3 at baseline.~Exclusion Criteria:~* Subject was previously treated with adalimumab or another anti-tumor necrosis factor (anti-TNF) therapy (e.g., infliximab or etanercept).~* Subject received any oral antibiotic treatment for HS within 28 days prior to Baseline.~* Subject received oral concomitant analgesics (including opioids) for HS-related pain within 14 days prior to Baseline visit.~* If entering the study on concomitant oral analgesics for non-HS related pain:~  * Subject on opioid analgesics within 14 days prior to Baseline visit;~ * Subject not on a stable dose of non-opioid oral analgesics for at least 14 days prior to the Baseline visit (as needed is not considered a stable dose).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for 12 weeks.
- Adalimumab Every Week (EW) (Type: EXPERIMENTAL): Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).
- Placebo/Adalimumab Every Week (EW) (Type: EXPERIMENTAL): Participants randomized to receive placebo in Period 1 received adalimumab 160 mg at Week 12, 80 mg at Week 14, and 40 mg ew from Week 16 to Week 35 in Period 2 (up to 24 weeks).
- Adalimumab Every Week (EW)/Placebo (Type: EXPERIMENTAL): Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
- Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW) (Type: EXPERIMENTAL): Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive adalimumab 40 mg eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).
- Adalimumab Every Week (EW)/Adalimumab Every Week (EW) (Type: EXPERIMENTAL): Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Give written informed consent~* Females must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal. Males must be surgically sterile, abstinent, or if engaged in sexual relations of child-bearing potential, must use contraception~* Undergoing elective, primary unilateral total knee arthroplasty~Exclusion Criteria:~* Body weight \<50 kg~* Patients at increased risk of bleeding. History of intracranial or intraocular bleeding. History of gastrointestinal and/or endoscopically verified ulcer disease within the past year.~* History of excessive intra- or direct post operative bleeding or a traumatic spinal or epidural anesthesia~* Brain, spinal, or ophthalmologic surgery within the past 3 months~* History of clinically significant liver disease in the past year~* Screening laboratory results as follows, or any other clinically significant abnormalities in screening laboratory values~  * aPTT or PT or INR \>ULN~ * Factor IX activity \<LLN~ * Factor VIII activity, vWF antigen or Ristocetin cofactor activity \<0.5 U/mL~ * FXI activity \<0.3 U/mL~ * Urine protein or blood persistently positive by dipstick. In the event of positive test results, eligibility may be confirmed with urine microscopy or 24 hour urine protein measurement as applicable~ * ALT or AST \>1.5 x ULN~ * Total bilirubin \>ULN~ * Platelet count \<150,000 (or history of thrombocytopenia)~* Hypersensitivity to enoxaparin~* Anticipated concomitant use of anticoagulants/antiplatelet agents or the NSAID nimesulide that may affect study outcome or any other drug influencing coagulation (except low dose aspirin and short acting NSAIDs with a half-life \<20 hours) at least 7 days before surgery or during treatment with ISIS Rx.~* Anticipated use of indwelling intrathecal or epidural catheters~* Anemia at Screening~* Have any other conditions which could interfere with the patient participating in or completing the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ISIS-FXIRx Dose 2 (Type: EXPERIMENTAL): Group B: ISIS-FXIRx Dose #2
- ISIS-FXIRx Dose 3 (Type: EXPERIMENTAL): Group C: ISIS-FXIRx Dose #3
- Enoxaparin (Type: ACTIVE_COMPARATOR): Enoxaparin (40mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete